German Drug Price Freeze Confirmed For Four Years In Latest Reforms
This article was originally published in The Pink Sheet Daily
Germany’s pharmaceutical sector reforms represent a mixed bag for industry, with the price freeze set to continue, while rebate levels to health insurers are slashed.
You may also be interested in...
With the German drug price freeze set to continue, the pharmaceutical industry wants to see at least an inflation-linked rise in prices and the abandonment of HTA for older products.
Germany’s senior reimbursement body, the G-BA, has announced it will assess a second wave of older drugs, despite a pending coalition agreement dropping this practice.
German coalition negotiation proposals will see government slash the obligatory rebate for pharma companies while continuing the current prize freeze. But old products will be exempt from HTA.